Biochemical and pharmacological characterization of different recombinant acid α-glucosidase preparations evaluated for the treatment of Pompe disease
Alison McVie‐Wylie, Robert J. Mattaliano, M. W. O'CALLAGHAN, William M. Canfield(Unknown), Russell Gotschall, Nina Raben(APT Therapeutics (United States)), K.L. Lee, Hung Do, Beth L. Thurberg(Sanofi (United States)), Xin Jin, Laura Andrews, J M McPherson, Hengheng Qiu, Chris Rogers
Cited by 96
Related Papers
Anticoagulant properties of bovine plasma protein C following activation by thrombin
|Biochemistry|1977|491
Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction
|Arthritis & Rheumatism|2005|345
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
|EMBO Molecular Medicine|2013|337
Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy
|Kidney International|2002|331
Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies
|Proceedings of the National Academy of Sciences|2000|314